These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444 [TBL] [Abstract][Full Text] [Related]
3. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775 [TBL] [Abstract][Full Text] [Related]
4. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713 [TBL] [Abstract][Full Text] [Related]
5. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Sharma K; Pant S; Misra S; Dwivedi M; Misra A; Narang S; Tewari R; Bhadoria AS Saudi J Gastroenterol; 2014; 20(4):225-32. PubMed ID: 25038208 [TBL] [Abstract][Full Text] [Related]
11. Rifaximin for the treatment of hepatic encephalopathy. Mullen K; Prakash R Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586 [TBL] [Abstract][Full Text] [Related]
12. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Goyal O; Sidhu SS; Kishore H Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800 [TBL] [Abstract][Full Text] [Related]
14. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Bajaj JS; Heuman DM; Wade JB; Gibson DP; Saeian K; Wegelin JA; Hafeezullah M; Bell DE; Sterling RK; Stravitz RT; Fuchs M; Luketic V; Sanyal AJ Gastroenterology; 2011 Feb; 140(2):478-487.e1. PubMed ID: 20849805 [TBL] [Abstract][Full Text] [Related]
15. The diagnosis and treatment of minimal hepatic encephalopathy. Zhan T; Stremmel W Dtsch Arztebl Int; 2012 Mar; 109(10):180-7. PubMed ID: 22470407 [TBL] [Abstract][Full Text] [Related]
16. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy. Direkze S; Jalan R Dig Dis; 2015; 33(4):562-9. PubMed ID: 26159274 [TBL] [Abstract][Full Text] [Related]
18. Durability of rifaximin response in hepatic encephalopathy. Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586 [TBL] [Abstract][Full Text] [Related]
19. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F; Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]